Ex-US revenue rose sharply by 21% YoY to Rs. 2, 240.4 crore ($254 million); Operational PAT grew 50.3% YoY to Rs. 518.1 crore
Inspection included drug device combinations covering our recent filing in nasal sprays domain
These observations are procedural in nature and the company does not anticipate any impact on supply of its commercial products
EBITDA rose to Rs. 218.1 crore, a 14.8% year-on-year increase
For the full year FY25, net profit soared 12x to Rs 345 crore
Amexel aims to generate revenue through facilitation services and a profit-sharing model linked to the commercialization of products
Scored 85/100, 2.3x the industry average in Social and 73/100, 1.8x the industry average in Governance
Dr. Muthu was last associated with Mankind Pharma
Strides Pharma Science has reported total income of Rs. 1,229.52 crores during the period ended September 30, 2024
The share subscription agreements are being executed at a pre-money equity value of US$ 1.65 billion
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
